The Changing Role of Chemoimmunotherapy (CIT) in CLL/SLL

CLL treatment has changed significantly over the past decade. So, where does chemoimmunotherapy fit today? In this video, Dr. Brian Koffman, a retired physician and CLL/SLL patient advocate, discusses how the CLL treatment landscape has evolved and the role of chemoimmunotherapy today. Dr. Koffman explains how newer targeted therapies, including BTK inhibitors and BCL2 inhibitors, have changed the way many people with CLL are treated. He also discusses why long-term outcomes are important to consider when evaluating treatment options. If you have questions about which CLL treatment may be appropriate for you, talk to your healthcare team. The bottom line: CLL treatment has evolved considerably, giving patients new options beyond traditional chemoimmunotherapy. Understanding the benefits and risks of different approaches can help you have a more informed conversation with your care team. Visit CLLNavigator.com for resources to help you along your CLL journey. #CLL #ChronicLymphocyticLeukemia #CLLTreatment #Chemoimmunotherapy #CLLNavigator